XAFS STUDIES OF METAL ANTI-DIABETIC SUPPLEMENTS AND DRUGS
金属抗糖尿病补充剂和药物的 XAFS 研究
基本信息
- 批准号:8362227
- 负责人:
- 金额:$ 0.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2012-02-29
- 项目状态:已结题
- 来源:
- 关键词:Antidiabetic DrugsBiochemical PathwayBiodistributionBiologicalBlood GlucoseCellsChromiumClinical TrialsDeveloped CountriesDiabetes MellitusExhibitsFundingGenerationsGrantIncidenceLinkMetabolic DiseasesMetalsMuscleNational Center for Research ResourcesNatureNon-Insulin-Dependent Diabetes MellitusObesityPharmaceutical PreparationsPhosphoric Monoester HydrolasesPrincipal InvestigatorProcessPropertyRadiationRelative RisksResearchResearch InfrastructureResourcesRoleSourceTechniquesTestingUnited States National Institutes of Healthbasebeamlinechromium hexavalent ioncostdesigndiabeticdietary supplementsoligomycin sensitivity-conferring proteinoxidationstructural biologyuptake
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Type 2 diabetes is a metabolic disorder characterised by an inability to control blood glucose concentrations. It is strongly linked to obesity, with the greatest incidence of diabetes occurring in the most developed countries. While phosphatase inhibition is the generally accepted mechanism to explain the anti-diabetic effects of V complexes there is much more controversy associated with the role of Cr supplements, and considerable debate still surrounds the exact mode of action, biodistribution and the functions associated with their efficacies. Chromium dietary supplements are the second most popular metal supplements after Ca supplements and are taken for their purported activities as anti-diabetic, slimming and muscle-building capacities. However, the efficacy in anti-diabetic effects is only observed at relatively high concentrations of supplements and we have demonstrated that these generate appreciable amounts of carcinogenic Cr(VI) both intra- and extra-cellularly and in a manner that appears to be dependent on the nature of the supplement. To study Cr speciation in bulk cells with XANES, third generation beamlines are required because of the low uptake of some common supplements. The use of such techniques will enable us to in ascertain whether the biological oxidations observed to date are common to all of the Cr supplements or just certain types. This may be important in assessing their relative risks. We will also investigate the anti-diabetic properties of V complexes that are in clinical trials or are promising candidates for trials. In particular, we will test our hypothesis that V exhibits these properties via the V(V) oxidation states or peroxo species generated by intracellular processes via similar biochemical pathways to those we have investigated in Cr. In doing so, we anticipate that we will be able to design safer and more effective metal-based anti-diabetic drugs.
该子项目是利用资源的众多研究子项目之一
由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持
并且子项目的主要研究者可能是由其他来源提供的,
包括其他 NIH 来源。 子项目可能列出的总成本
代表子项目使用的中心基础设施的估计数量,
NCRR 赠款不直接向子项目或子项目工作人员提供资金。
2 型糖尿病是一种代谢性疾病,其特征是无法控制血糖浓度。它与肥胖密切相关,在大多数发达国家,糖尿病的发病率最高。虽然磷酸酶抑制是解释 V 复合物抗糖尿病作用的普遍接受的机制,但与 Cr 补充剂的作用相关的争议更多,并且围绕其确切的作用方式、生物分布及其功效相关的功能仍然存在相当大的争议。铬膳食补充剂是继钙补充剂之后第二受欢迎的金属补充剂,据称具有抗糖尿病、减肥和增强肌肉的作用。然而,只有在相对较高浓度的补充剂中才能观察到抗糖尿病作用的功效,我们已经证明,这些补充剂会在细胞内和细胞外产生大量的致癌 Cr(VI),其产生方式似乎取决于补充剂的性质。为了使用 XANES 研究散装电池中的 Cr 形态,需要使用第三代光束线,因为一些常见补充剂的吸收率较低。使用此类技术将使我们能够确定迄今为止观察到的生物氧化是否对所有 Cr 补充剂或仅某些类型是常见的。这对于评估其相对风险可能很重要。我们还将研究正在进行临床试验或有希望进行试验的 V 复合物的抗糖尿病特性。特别是,我们将测试我们的假设,即 V 通过 V(V) 氧化态或细胞内过程产生的过氧物种(通过与我们在 Cr 中研究的相似的生化途径)表现出这些特性。通过这样做,我们预计我们将能够设计出更安全、更有效的金属抗糖尿病药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER A LAY其他文献
PETER A LAY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER A LAY', 18)}}的其他基金
XAFS STUDIES OF METAL ANTI-DIABETIC SUPPLEMENTS AND DRUGS
金属抗糖尿病补充剂和药物的 XAFS 研究
- 批准号:
8170187 - 财政年份:2010
- 资助金额:
$ 0.19万 - 项目类别:
XAFS STUDIES OF METAL ANTI-DIABETIC SUPPLEMENTS AND DRUGS
金属抗糖尿病补充剂和药物的 XAFS 研究
- 批准号:
7954532 - 财政年份:2009
- 资助金额:
$ 0.19万 - 项目类别:
INTRACELLULAR XAS ON CULTURED MAMMALIAN CELLS TREATED WITH CR CARCINOGENS & DIET
用 CR 致癌剂处理的培养哺乳动物细胞的细胞内 XAS
- 批准号:
7598011 - 财政年份:2007
- 资助金额:
$ 0.19万 - 项目类别:
INTRACELLULAR XAS ON CULTURED MAMMALIAN CELLS TREATED WITH CR CARCINOGENS & DIET
用 CR 致癌剂处理的培养哺乳动物细胞的细胞内 XAS
- 批准号:
7370493 - 财政年份:2006
- 资助金额:
$ 0.19万 - 项目类别:
相似海外基金
Improving the quality and coherence of biochemical pathway information resources and developing tools to facilitate the investigation of intestinal microflora
提高生化途径信息资源的质量和一致性,开发促进肠道微生物群研究的工具
- 批准号:
442760-2013 - 财政年份:2013
- 资助金额:
$ 0.19万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
MouseCyc: A Biochemical Pathway Database for the Mouse
MouseCyc:小鼠生化通路数据库
- 批准号:
7351830 - 财政年份:2006
- 资助金额:
$ 0.19万 - 项目类别:
MouseCyc: A Biochemical Pathway Database for the Mouse
MouseCyc:小鼠生化通路数据库
- 批准号:
7215571 - 财政年份:2006
- 资助金额:
$ 0.19万 - 项目类别:
MouseCyc: A Biochemical Pathway Database for the Mouse
MouseCyc:小鼠生化通路数据库
- 批准号:
7033357 - 财政年份:2006
- 资助金额:
$ 0.19万 - 项目类别:














{{item.name}}会员




